Daniel  Vitt net worth and biography

Daniel Vitt Biography and Net Worth

CEO of Immunic
Daniel Vitt, Ph.D., joined Immunic in January 2017, and subsequent to the company’s reverse takeover transaction with Vital Therapies in 2019, has served as Chief Executive Officer, President and Director of Immunic, Inc. Previously, he was Chief Scientific Officer and Chief Development Officer of 4SC AG, a publicly traded company based in Germany that he co-founded in 1997. While there, he successfully grew the company from the research stage into an advanced therapeutic development company with several clinical-stage product candidates in the pipeline.

Dr. Vitt studied chemistry in Siegen and Würzburg, Germany, and graduated from the University of Würzburg, where he focused on quantum-chemical calculations of organic reactions. He received his Ph.D. from the Institute of Organic Chemistry at the University of Würzburg, where he focused on molecular design of small molecule therapeutics.

Dr. Vitt is currently a member of the advisory board of the venture capital fund “Wachstumsfond Bayern 2,” managed by Bayern Kapital GmbH. In 2018, he also co-founded Brauhaus Germering GmbH, a local German specialty brewery.

What is Daniel Vitt's net worth?

The estimated net worth of Daniel Vitt is at least $414,564.70 as of November 22nd, 2022. Dr. Vitt owns 376,877 shares of Immunic stock worth more than $414,565 as of November 23rd. This net worth approximation does not reflect any other assets that Dr. Vitt may own. Additionally, Dr. Vitt receives a salary of $869,960.00 as CEO at Immunic. Learn More about Daniel Vitt's net worth.

How old is Daniel Vitt?

Dr. Vitt is currently 56 years old. There are 5 older executives and no younger executives at Immunic. Learn More on Daniel Vitt's age.

What is Daniel Vitt's salary?

As the CEO of Immunic, Inc., Dr. Vitt earns $869,960.00 per year. Learn More on Daniel Vitt's salary.

How do I contact Daniel Vitt?

The corporate mailing address for Dr. Vitt and other Immunic executives is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. Immunic can also be reached via phone at (332) 255-9818 and via email at [email protected]. Learn More on Daniel Vitt's contact information.

Has Daniel Vitt been buying or selling shares of Immunic?

Daniel Vitt has not been actively trading shares of Immunic during the last quarter. Most recently, on Tuesday, November 22nd, Daniel Vitt bought 8,000 shares of Immunic stock. The stock was acquired at an average cost of $1.35 per share, with a total value of $10,800.00. Following the completion of the transaction, the chief executive officer now directly owns 376,877 shares of the company's stock, valued at $508,783.95. Learn More on Daniel Vitt's trading history.

Who are Immunic's active insiders?

Immunic's insider roster includes Duane Nash (Chairman), Daniel Vitt (CEO), and Glenn Whaley (Insider). Learn More on Immunic's active insiders.

Are insiders buying or selling shares of Immunic?

In the last twelve months, Immunic insiders bought shares 1 times. They purchased a total of 87,300 shares worth more than $100,395.00. The most recent insider tranaction occured on November, 12th when Director Richard Alan Rudick bought 87,300 shares worth more than $100,395.00. Insiders at Immunic own 3.0% of the company. Learn More about insider trades at Immunic.

Information on this page was last updated on 11/12/2024.

Daniel Vitt Insider Trading History at Immunic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2022Buy8,000$1.35$10,800.00376,877View SEC Filing Icon  
6/3/2022Buy5,000$3.10$15,500.00368,877View SEC Filing Icon  
8/10/2021Buy1,000$9.60$9,600.0015,032View SEC Filing Icon  
7/21/2020Sell6,300$14.68$92,484.00View SEC Filing Icon  
See Full Table

Daniel Vitt Buying and Selling Activity at Immunic

This chart shows Daniel Vitt's buying and selling at Immunic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immunic Company Overview

Immunic logo
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Read More

Today's Range

Now: $1.10
Low: $1.06
High: $1.12

50 Day Range

MA: $1.40
Low: $1.05
High: $1.95

2 Week Range

Now: $1.10
Low: $0.97
High: $2.11

Volume

787,509 shs

Average Volume

620,246 shs

Market Capitalization

$99.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.88